Replimune Group, Inc.
REPL
Rank in Stocks
#5737
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering... Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
Share Price
$22.26
Last synced: 2026-11-09
Market Cap
$2.11B
Change (1 day)
2.96%
Change (1 year)
143.81%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Replimune Group, Inc. (REPL)
Category
Healthcare
EPS for Replimune Group, Inc. (REPL)
EPS as of September 2026 TTM: $-2.79
According to Replimune Group, Inc.'s latest financial reports, its current EPS (TTM) is $-2.79. At the end of 2025 the company had an EPS of $-3.07, an increase over its 2024 EPS of $-3.24.
EPS history for Replimune Group, Inc. from 2017 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-2.79 | -9.12% |
| 2025 | $-3.07 | -5.25% |
| 2024 | $-3.24 | 8.36% |
| 2023 | $-2.99 | 32.30% |
| 2022 | $-2.26 | 29.14% |
| 2021 | $-1.75 | 13.64% |
| 2020 | $-1.54 | 15.79% |
| 2019 | $-1.33 | 107.81% |
| 2018 | $-0.64 | 77.78% |
| 2017 | $-0.36 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -661.29% |
US
|
|
| $-7.07 | 153.41% |
US
|
|
| $-5.29 | 89.61% |
AU
|
|
| $12.88 | -561.65% |
BE
|
|
| $21.56 | -872.76% |
NL
|
Questions about Replimune Group, Inc.'s earnings per share (EPS)
What is Replimune Group, Inc.'s earnings per share (EPS)?
Replimune Group, Inc.'s earnings per share (EPS) over the last twelve months is $-2.79, as of Sep 2026.
What was Replimune Group, Inc.'s earnings per share (EPS) in 2025?
In 2025, Replimune Group, Inc.'s earnings per share (EPS) was $-3.07, compared with $-3.24 in 2024.
How has Replimune Group, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Replimune Group, Inc.'s earnings per share (EPS) was highest in 2020 ($-1.54) and lowest in 2024 ($-3.24).
How does Replimune Group, Inc.'s earnings per share (EPS) compare with similar companies?
Replimune Group, Inc.'s earnings per share (EPS) ($-2.79) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.